Artemis Medicare Services held its Board of Directors meeting on May 8, 2026, approving the audited financial results for the quarter and year ended March 31, 2026, on both standalone and consolidated bases. The board recommended a final dividend of Re. 0.45 per equity share of face value Re. 1 each (i.e., 45%) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board appointed Mr. Tapan Mitra as an Additional Director in the capacity of Independent Director for a period of 3 years, effective from May 8, 2026, subject to AGM approval. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results for the quarter and year ended March 31, 2026 were subsequently published in The Financial Express (English National Daily Newspaper – all editions) and The Jansatta (Hindi National Daily Newspaper – Delhi edition) on May 9, 2026.

Standalone Financial Performance

On a standalone basis, the company reported revenue from operations of ₹27,378.66 lacs for Q4 FY26, compared to ₹23,480.13 lacs in the previous year. Net profit after tax for the quarter stood at ₹2,954.70 lacs against ₹2,320.46 lacs in Q4 FY25. For the full year FY26, standalone revenue from operations reached ₹1,06,049.17 lacs, up from ₹91,326.13 lacs in FY25, while net profit after tax increased to ₹10,344.15 lacs from ₹8,345.78 lacs. The company recognized an exceptional item of ₹307.44 lacs during the year, representing the incremental impact on gratuity and leave liability arising from the Labour Codes notified by the Government of India.

* Not annualised

Consolidated Financial Performance

On a consolidated basis, encompassing Artemis Medicare Services Limited and its subsidiary Artemis Cardiac Care Private Limited, the group reported revenue from operations of ₹27,922.64 lacs for Q4 FY26, up 16.4% from ₹23,990.01 lacs in Q4 FY25. Consolidated net profit after tax for the quarter stood at ₹3,028.10 lacs, a growth of 32.1% against ₹2,292.39 lacs in the previous year. For the full year FY26, consolidated revenue from operations rose 15.4% to ₹1,08,124.24 lacs from ₹93,691.67 lacs in FY25. Consolidated net profit after tax for the year stood at ₹10,371.52 lacs, a growth of 26.2% against ₹8,217.62 lacs in the previous year, while consolidated EBITDA grew 18.0% to ₹21,801 lacs from ₹18,478 lacs.

* Not annualised

Artemis Hospital Gurgaon Operational Highlights

The flagship Artemis Hospital Gurgaon facility was a key driver of performance during the period. For Q4 FY26, revenue from operations stood at ₹26,746 lacs, an increase of 18.8% from ₹22,520 lacs in Q4 FY25. EBITDA for the quarter grew 20.6% to ₹5,804 lacs, while PAT increased 19.8% to ₹3,136 lacs. The hospital reported an Average Revenue Per Occupied Bed (ARPOB) of ₹84,571 and bed capacity utilization of 64.6%. For the full year FY26, the facility recorded revenue of ₹1,03,022 lacs, up 17.8% from ₹87,424 lacs in FY25, with an EBITDA of ₹21,785 lacs and PAT of ₹11,336 lacs.

Corporate Actions and Governance

The board approved the re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for a second term of 5 years, from the conclusion of the 22nd AGM to the 27th AGM (year 2031), subject to AGM approval. Additionally, the board approved the extension of the period for utilization of unutilized funds from the proceeds of the preferential issue by 18 months, without any change in the objects of the issue. The company also entered into a Medical Services Agreement with Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre (VIMHANS), paying an advance of ₹6,962 lacs during the quarter ended March 31, 2026, aggregating to ₹12,862 lacs as at that date, and providing a bank guarantee of ₹5,900 lacs.

Artemis Medicare Services Limited has notified the stock exchanges of an amendment to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended Code was approved by the Board of Directors on May 8, 2026, and has been uploaded on the company's website at www.artemishospitals.com/investors . The intimation was submitted by Poonam Makkar, Company Secretary and Compliance Officer.

Code Overview and Effective Dates

The Code was originally adopted at a Board meeting and has since been periodically reviewed and updated. The key dates associated with the Code are as follows:

Objective and Scope

The Code is designed to ensure timely and adequate disclosure of UPSI that may impact the price of the company's securities, while maintaining uniformity, transparency, and fairness in dealings with all stakeholders. It also aims to preserve the confidentiality of UPSI and prevent its misuse. The Code applies to all persons within the organisation who may come into possession of price-sensitive information.

Key Norms for Fair Disclosure

The amended Code sets out a comprehensive framework of norms governing the handling and dissemination of UPSI. The principal requirements include:

• Prompt public disclosure of UPSI that would impact price discovery, as soon as credible and concrete information comes into being
• Uniform and universal dissemination of UPSI to all Stock Exchanges and on the company's official website to avoid selective disclosure
• Restricted external communication, with only designated Authorised Spokespersons permitted to discuss company matters with media, investors, and the investment community
• Prompt remediation in cases where UPSI is disclosed selectively or inadvertently, through immediate dissemination to Stock Exchanges and the company's website
• Fair and appropriate responses to queries on news reports and requests for verification of market rumours from regulatory authorities
• Need-to-know basis handling of all UPSI within the organisation

Authorised Spokespersons

Unless otherwise approved by the Managing Director, only individuals in the following designated positions are authorised to communicate company matters externally:

• Chairman
• Managing Director
• Chief Financial Officer
• Chief Business Officer
• Head – Investor Relations, M&A and Organization Growth Strategy
• Chief People Officer

Analyst Interactions and Record-Keeping

The Code specifies that the company shall provide only public information to analysts, research personnel, investor groups, and institutional investors. At least two Authorised Representatives are required to be present at all meetings and conference calls with analysts to prevent misquoting or misrepresentation. Transcripts and recordings of such meetings are to be uploaded on the company's website in accordance with applicable laws.

Confidentiality Safeguards and Legitimate Purpose Policy

Persons privy to UPSI are required to adopt specific safeguards to preserve confidentiality, including maintaining secure physical files, password-protected computer access, and deletion or destruction of confidential files after use. The Code also incorporates a Policy for Determination of Legitimate Purpose, framed under Regulation 3(2A) of the SEBI Insider Trading Regulations. This policy outlines factors to assess whether sharing of UPSI in a given instance constitutes a legitimate purpose, including whether the sharing is in the ordinary course of business, in the best interests of the company, or required to fulfil legal or contractual obligations. A structured digital database is to be maintained internally—with time stamping and audit trails—recording the nature of UPSI shared and the identities of persons involved, including their Permanent Account Numbers or other authorised identifiers.